Breast cancer patients at risk of both cardiovascular disease and T2D may have higher long-term morbidity, stressing the need for studies clarifying the impact of anti-HER2 therapy on the risk of T2D. The gene discussed is ERBB2; the disease is cardiovascular disorder.